Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

06/20
2017

With Patients Reporting Symptoms Using Web Tool, Survival Improves

An online tool that allows metastatic cancer patients to report their symptoms and grade them on severity is helping improve their survival, according to a study reported at the recent meetings of the American Society of Clinical Oncology m…

06/7
2017

Combined immune checkpoint blockade shows promise for small cell lung cancer

Small Cell Lung Cancer news: The combination of nivolumab plus ipilimumab led to durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial presented at the 2017 ASCO Annu…

06/7
2017

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Learn more More Lung Cancer Research News:…

05/22
2017

Lab on a Chip Outlines New Liquid Biopsy Technology

Lab on a Chip publication outlines a new technology that may be an important tool for liquid biopsies. Read the UCLA Patient Newsletter: http://lcfamerica.org/wp-content/uploads/2017/05/Issue-52-for-April-TOTR-Patient-Newsletter.pdf …

05/18
2017

A newly released study shows that Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not pro…

05/12
2017

FDA Approves Keytruda Combo for Lung Cancer

The Food and Drug Administration (FDA) has granted an accelerated approval to Keytruda (pembrolizumab) for use in combination with chemotherapy as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell l…

05/4
2017

Brigatinib

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progress…

05/1
2017

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

[caption id="attachment_1562" align="aligncenter" width="850"] Senior woman with lung cancer during medical visit[/caption] FDA Grants Lorlatinib Breakthrough Designation for NSCLC: “This regulatory designation recognizes the potential for…

04/28
2017

DNA-based test can spot cancer recurrence a year before conventional scans

A revolutionary blood test has been shown to diagnose the recurrence of cancer up to a year in advance of conventional scans in a major lung cancer trial. Read more: https://www.theguardian.com/society/2017/apr/26/dna-based-test-can-spo…

04/18
2017

Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for…



Read More